FENTANYL REMAINING IN A TRANSDERMAL SYSTEM FOLLOWING 3 DAYS OF CONTINUOUS USE

被引:69
作者
MARQUARDT, KA [1 ]
THARRATT, RS [1 ]
MUSALLAM, NA [1 ]
机构
[1] UNIV CALIF SAN FRANCISCO,SCH PHARM,SAN FRANCISCO,CA
关键词
D O I
10.1177/106002809502901001
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
OBJECTIVE: TO determine whether there was a sufficient amount of fentanyl remaining in a patch that had been used continuously for 3 days to warrant establishment of disposal policies to prevent diversion of fentanyl. DESIGN: Nine patches were applied and removed by hospice nurses after 3 days of continuous use on hospice patients with cancer. Patches were analyzed for the remaining fentanyl contents using the Coat-A-Count Fentanyl radioimmunoassay. Five 2.5-mg patches and four 10.0-mg patches were opened, solubilized with methanol, diluted with water, and analyzed in duplicate. An unused 2.5-mg patch also was analyzed as a control and showed a 94% recovery of fentanyl. A methanol blank was negative for fentanyl. MAIN OUTCOME MEASURES: The study determined the amount of fentanyl in milligrams remaining in a used patch. Using pharmacokinetic principles, this quantity was compared with a potential lethal dose of fentanyl. RESULTS: Analysis showed 0.7-1.22 mg remaining in the 2.5-mg patches and 4.46-8.44 mg remaining in the 10.0-mg patches. These numbers represent 28-84.4% of the original contents. Using the pharmacokinetic values of the volume of distribution of 4 L/kg and a potential lethal blood concentration of 3.7 mu g/L, one can calculate the potential lethal dose for a 70-kg person to be 1036 mu g. This is well within the amount remaining in the patch. This study also demonstrated that a wide patient variability exists in the absorption of fentanyl from the patch. CONCLUSIONS: There is a sufficient amount of fentanyl available for abuse and misuse after 3 days of therapeutic use. Adequate disposal policies currently are not established and need to be implemented.
引用
收藏
页码:969 / 971
页数:3
相关论文
共 11 条
[1]  
BASELT RC, 1989, DISPOSITION TOXIC DR, P351
[2]   INTRAVENOUS ABUSE OF TRANSDERMAL FENTANYL THERAPY IN A CHRONIC PAIN PATIENT [J].
DESIO, JM ;
BACON, DR ;
PEER, G ;
LEMA, MJ .
ANESTHESIOLOGY, 1993, 79 (05) :1139-1141
[3]   INHALATION ABUSE OF FENTANYL PATCH [J].
MARQUARDT, KA ;
THARRATT, RS .
JOURNAL OF TOXICOLOGY-CLINICAL TOXICOLOGY, 1994, 32 (01) :75-78
[4]  
MCEVOY GK, 1992, ASHP DRUG INFORMATIO, P1135
[5]   SENSITIVE RADIOIMMUNOASSAY FOR FENTANYL - PLASMA-LEVEL IN DOGS AND MAN [J].
MICHIELS, M ;
HENDRIKS, R ;
HEYKANTS, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1977, 12 (02) :153-158
[6]   TRANSDERMAL FENTANYL FOR CANCER PAIN - REPEATED DOSE PHARMACOKINETICS [J].
PORTENOY, RK ;
SOUTHAM, MA ;
GUPTA, SK ;
LAPIN, J ;
LAYMAN, M ;
INTURRISI, CE ;
FOLEY, KM .
ANESTHESIOLOGY, 1993, 78 (01) :36-43
[7]   FENTANYL TRANSDERMAL SYSTEM OVERDOSE SECONDARY TO CUTANEOUS HYPERTHERMIA [J].
ROSE, PG ;
MACFEE, MS ;
BOSWELL, MV .
ANESTHESIA AND ANALGESIA, 1993, 77 (02) :390-391
[8]   ABSORPTION CHARACTERISTICS OF TRANSDERMALLY ADMINISTERED FENTANYL [J].
VARVEL, JR ;
SHAFER, SL ;
HWANG, SS ;
COEN, PA ;
STANSKI, DR .
ANESTHESIOLOGY, 1989, 70 (06) :928-934
[9]   EVALUATION OF THE COAT-A-COUNT I-125 FENTANYL RIA - COMPARISON OF I-125 RIA AND GC/MS-SIM FOR QUANTIFICATION OF FENTANYL IN CASE URINE SPECIMENS [J].
WATTS, VW ;
CAPLAN, YH .
JOURNAL OF ANALYTICAL TOXICOLOGY, 1990, 14 (05) :266-272
[10]   ASSAY-METHODS FOR FENTANYL IN SERUM - GAS-LIQUID-CHROMATOGRAPHY VERSUS RADIOIMMUNOASSAY [J].
WOESTENBORGHS, RJH ;
STANSKI, DR ;
SCOTT, JC ;
HEYKANTS, JJP .
ANESTHESIOLOGY, 1987, 67 (01) :85-90